Evidence map›Paper›PMID 37959818›Full record

ArticleMolecules (Basel, Switzerland)2023

Phyllanthi Tannin Loaded Solid Lipid Nanoparticles for Lung Cancer Therapy: Preparation, Characterization, Pharmacodynamics and Safety Evaluation.

Baojin Wang, Kai Wu, Runping Liu, Ya Huang, Zihao Chang, Ye Gao, Yuqi Liu, Hongjiao Chen, Zhaohui Wang, Yitong Cui and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Baojin WangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Kai WuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Runping LiuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Ya HuangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Zihao ChangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Ye GaoSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Yuqi LiuSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Hongjiao ChenSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Zhaohui WangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Yitong CuiSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Le WangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Pengkai MaSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.
Lanzhen ZhangSchool of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, China.ORCID 0000-0003-4802-0433
Beijing University of Chinese Medicine · CN

Funding

the Key Project of Ministry of Science and Technology, PRC 2018ZX09711001-003-025the National Natural Science Foundation of China 82104404
6 · The paper itself

Abstract

The objective of the present study was to develop PTF-loaded solid lipid nanoparticles (PTF-SLNs) and investigate their efficacy in treating lung cancer. The PTF-SLNs were prepared by the thin film hydration method and verified by FTIR and TEM. Their physicochemical properties were characterized by particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE), drug loading (DL), etc. Then, the pharmacodynamic studies of PTF-SLNs were performed on Lewis lung cancer cells and tumor-bearing mice. Finally, the safety studies were assessed by organ index, serum biochemical indicators, and histopathological changes. The PTF-SLNs were characterized by around 50 nm sphere nanoparticles, sustained ideal stability, and controlled drug release effects. The pharmacodynamic evaluation results showed that PTF-SLNs had stronger anti-tumor efficacy than PTF. An in vitro study revealed a more obvious cytotoxicity and apoptosis effect. The IC 50 values of PTF and PTF-SLNs were 67.43 μg/mL and 20.74 μg/mL, respectively. An in vivo study showed that the tumor inhibition rates of 2 g/kg PTF and 0.4 g/kg PTF-SLNs were 59.97% and 64.55%, respectively. The safety preliminary study indicated that PTF-SLNs improve the damage of PTF to normal organs to a certain extent. This study provides a nanoparticle delivery system with phenolic herbal extract to improve anti-tumor efficacy in lung cancer.

Indexed as

Lung NeoplasmsNanoparticlesAnimalsDrug CarriersLipidsLiposomesMiceParticle SizeTanninsDrug CarriersLipid NanoparticlesLipidsLiposomesTanninsanti-tumorlung cancerPhyllanthus emblica L.polyphenolsafety evaluationsolid lipid nanoparticles

Identifiers

PMID37959818
PMCPMC10647271
OpenAlexW4388221787

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.